English
The Deeplex-MycTB solution presented in Les Echos
Check out the Les Echos article on our innovative Deeplex-MycTB solution, a next-generation test for combating multidrug-resistant TB.
GenoScreen in La Gazette of Nord-Pas de Calais
Discover La Gazette Nord-Pas de Calais article about our company "GenoScreen dissects DNA"
Become a GenoScreen Team Member
Join the GenoScreen team, we are looking for a Technical Sales Engineer, Genomics Specialty, apply!
GenoScreen's ISO certifications confirmed
Bureau Veritas Certification has renewed GenoScreen's ISO 9001:2015 and ISO 13485:2016 certifications for 3 years, demonstrating our continuous commitment to quality and efforts to satisfy our customers as best as possible, in compliance with legal and regulatory requirements.
How do genomics and genotyping contribute to species preservation?
Biodiversity, species preservation, ecosystem protection...
All are hot topics to which GenoScreen's genotyping solutions provide answers.
A new positive evaluation of Deeplex® Myc-TB
The innovative Deeplex® Myc-TB test for antibiotic resistance prediction in tuberculosis, created by GenoScreen, has been evaluated by an Indian research team. By testing approximately 40 clinical samples, this study validates the use of Deeplex® Myc-TB, by demonstrating its usability in hospital environments. These results confirm the interest of its deployment in hospital routines for the benefit of patients' health.
Next trainings
Sign up for our command line trainings at NGS data analysis from October 7 to 10, 2019.
Subcategories
GenoScreen
Partners
At GenoScreen, our genomics expertise is built on collaboration with a dense network of scientific, industrial and institutional partners. These partnerships strengthen our ability to innovate, co-develop new technologies and advance research in molecular microbiology.
A network of strategic partners
We actively collaborate with:
Research institutes, universities and hospitals
Competitive clusters specialized in biotechnology and healthcare
Public funding bodies
A co-development strategy
Our research projects are carried out with recognized partners in France and abroad. Together, we can :
- Co-develop innovative genomics and bioinformatics solutions
- Reply to national and international applications for projects (Horizon Europe, ANR, etc.)
- Test and validate our technologies in a variety of environments
- Launch the implementation of concrete solutions for health, agriculture and the environment
Why collaborate with GenoScreen?
- Access to an innovative sequencing technology platform
- Access to recognized expertise in bioinformatics analysis and biomarkers
- Benefit from our ability to manage collaborative R&D projects
- Strive for health, agriculture and environment
Join our network of partners
Do you represent a company, laboratory or public body? Contact us to discuss a collaboration or partnership.
Frequently asked questions
What kind of partners work with GenoScreen?
GenoScreen works with academic laboratories, biotech companies and clusters.
What are the benefits of these partnerships?
They help us co-develop technologies, co-finance projects and accelerate innovation.
How can I propose a partnership?
You can contact us via our contact form to discuss your project and identify a potential collaboration.
Collaborative research - At the heart of international innovation in genomics
GenoScreen is a partner in collaborative research projects that bring together startups, multinationals and public-sector organizations. Our R&D teams provide their knowledge and expertise in the molecular microbiology of isolated agents and complex communities. This allowed our teams to develop our own projects for elaborating innovative products and services.
Our projects are designed to:
- Improve the diagnosis and management of acute/chronic diseases on humans and animals,
- Characterize and monitor microbial biodiversity, with applications in agronomy, agrifood and environment.
The common feature of these projects is the development of molecular tools for the characterization, monitoring and diagnosis of microbial communities. The key objective is to market simple analytical solutions and (ultimately) preventive, corrective or even therapeutic products based on microorganisms.